Many of our followers on social media will remember Mary Huckle and her tireless campaigning for #metastaticbreastcancer awareness. This blog post is the last content she wrote for us, a
The Irony of Metastatic Breast Cancer – Mary Huckle
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS.
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS. The Scottish Medicines Consortium (SMC) has accepted: Trastuzumab deruxtecan (Enhertu)
Piqray (Alpelisib) denied by Scottish Medicines Consortium
The Scottish Medicines Consortium (SMC) have decided against funding the metastatic breast cancer drug alpelisib (Piqray).
Philippa Hetherington Remembered
We had to confirm back on the 5th November the heartbreaking news that the wonderful Philippa Hetherington had died 💔
She was an absolute force of intellectual nature for breast cancer in general, not just Inflammatory Breast Cancer.
Did you know that the Trodelvy campaign in England for TNBC was HER campaign?
Targeted treatment Piqray with Fulvestrant is approved
METUPUK welcomes the approval of Piqray (alpelisib) plus fulvestrant for the treatment of hormone receptor-positive, HER2-negative, PIK3CA- mutated advanced breast cancer.
Piqray is an exciting new cancer medicine because it is the first targeted treatment option for advanced breast cancer that has a PIK3CA mutation.
Trodelvy Now! Latest Update
METUPUK are delighted that NICE has accepted Trodelvy (sacituzumab govitecan) for routine use on the NHS in England for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior lines of systemic therapies. This follows on from the decision to approve Trodelvy in NHS Scotland in March 2022. Wales and Northern Ireland normally follow decisions by NHS England and we hope that Trodelvy will be made available to every patient who is eligible without delay.
Don’t Leave Metastatic Breast Cancer Patients in Wales Behind
A new campaign in Wales, by MetUpUK member Tassia Haines, aims to draw attention to the fact that Metastatic Breast Cancer (MBC) patients feel that they are being failed by the Welsh Government.
Join us as Laura, Mary Helen & Emily discuss primary & secondary breast cancer.
Have you ever wondered what the relationship is like between primary and secondary breast cancer patients when they are talking about cancer?
We’ve put 4 of our MetUpUK members on a zoom call to chat it out – Mary and Laura have secondary cancer and Helen and Emily have had primary breast cancer.
Trodelvy is approved by the Scottish Medicines Consortium (SMC) for Metastatic Triple Negative Breast Cancer for use by NHS Scotland
METUPUK welcomes the Scottish Medicines Consortium (SMC) acceptance of Trodelvy® (sacituzumab govitecan) for use within NHSScotland.
Trodelvy is an innovative drug which has been accepted for the treatment metastatic triple-negative breast cancer (mTNBC) within NHSScotland. Metastatic triple-negative breast cancer is a challenging disease to treat, and an even more devastating disease to live with.
Tucatinib is approved by NICE for HER2+ metastatic breast cancer
METUPUK welcome the National Institute of Clinical Excellence (NICE) decision to accept Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies for routine commissioning use in NHS in England and Wales.